Expert Review: Beyond Second-Line Treatment for Metastatic Breast Cancer - priME Oncology
Expert Review
Expert Review

Expert Review: Beyond Second-Line Treatment for Metastatic Breast Cancer

Not a member of My prIME? Join now for instant access.

Expert Review: Beyond Second-Line Treatment for Metastatic Breast Cancer

View Activity

Activity Overview

This CME-certified Expert Review, featuring an interactive video with clinical opinion poll questions and downloadable slides, focuses on the treatment of metastatic breast cancer, specifically beyond second-line treatment.


  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom


  • Joyce O’Shaughnessy, MDBaylor University Medical Center
    Texas Oncology
    US Oncology
    Dallas, Texas, United States
  • Denise Yardley, MDSarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee, United States


  • Chemotherapy for advanced breast cancer, particularly beyond second-line, for patients with estrogen receptor–positive and triple-negative breast disease
  • Goals of chemotherapy beyond second-line
  • Selection of optimal therapy
  • Balancing treatment efficacy and adverse event management
  • Agents used beyond the second-line, including epothilones
  • Ongoing trials
  • Novel agents

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Incorporate therapies for advanced/metastatic breast cancer into individualized treatment plans for patients based upon an evaluation of efficacy and safety data, as well as patient and tumor characteristics
  • Assess clinical trial data for the use of epothilones in (neo)adjuvant therapy and combinations with targeted treatment
  • Identify common or significant adverse events associated with treatment of advanced/metastatic breast cancer beyond the second-line setting, and the effective strategies for their prevention and/or management

Target Audience

This educational activity is specifically designed for medical oncologists, fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers who treat/manage patients with metastatic breast cancer.

View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity is supported by a grant from R-Pharm US.

Activity Date

March 2, 2016

October 31, 2017